NCT04410081

A Study of (14C)-JNJ-73841937 (Lazertinib) in Healthy Male Participants

An Open-Label Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-JNJ-73841937 (Lazertinib) After a Single Oral Dose in Healthy Male Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: Male
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to characterize the absorption, metabolic pathways of lazertinib, and the excretion of the parent lazertinib and its metabolites, after a single oral dose of 14C-lazertinib in healthy adult male participants.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	14C-lazertinib	A single oral dose of 14C-lazertinib will be administered.

Timeline

• Start date: 2020-07-14
• Primary completion: 2021-03-02
• Completion: 2021-03-02
• First posted: 2020-06-01
• Last updated: 2021-03-29

Locations

1 site across 1 country: Netherlands

Regulatory

• FDA-regulated drug study